Hemorheology and Hypertension in End-Stage Renal Failure Patients Treated with Erythropoietin
With the advent of recombinant human erythropoietin (r-HuEPO) effective treatment of renal anemia has become possible (1–3). However, with the increase of hematocrit levels some of the patients treated developed hypertension. Since blood viscosity determines vascular resistance (4, 5) and thereby blood pressure (6, 7), we investigated blood pressure behaviour and blood viscosity in long-term dialysis patients during treatment with r-HuEPO.
KeywordsDialysis Patient Hemodialysis Patient Blood Viscosity Hematocrit Level Recombinant Human Erythropoietin
Unable to display preview. Download preview PDF.
- 5.Harris, T., McLoughlin, G. Q. J. Med. 23: 451–464, 1930.Google Scholar
- 7.Leschke, M., Motz, W., Blanke, H., and Strauer, B.E. J. Cardiovasc. Pharm. 10 (Suppl. 6): 103–110, 1987.Google Scholar
- 8.Neff, M.S., Kim, K.E., Persoff, M., Onesti, G., and Swartz, C. Circulation 18: 876–883, 1971.Google Scholar